Novavax Target of Unusually Large Options Trading (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) saw unusually large options trading on Wednesday. Stock investors bought 19,222 put options on the stock. This represents an increase of 48% compared to the average daily volume of 12,997 put options.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. BTIG Research started coverage on Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price target for the company. TD Cowen raised shares of Novavax to a "hold" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $18.00.

Institutional Investors Weigh In On Novavax

A number of large investors have recently bought and sold shares of NVAX. GF Fund Management CO. LTD. bought a new stake in Novavax in the 4th quarter valued at about $27,000. Spire Wealth Management bought a new stake in Novavax during the 4th quarter worth approximately $29,000. New Age Alpha Advisors LLC purchased a new stake in shares of Novavax in the fourth quarter worth approximately $35,000. KBC Group NV raised its stake in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 3,917 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Novavax by 2,272.5% during the first quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 11,340 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Performance

Shares of NASDAQ NVAX traded down $0.20 during midday trading on Friday, reaching $6.00. The company's stock had a trading volume of 4,866,614 shares, compared to its average volume of 8,261,801. The company has a market cap of $965.06 million, a P/E ratio of -2.65, a P/E/G ratio of 2.85 and a beta of 3.15. Novavax has a fifty-two week low of $3.90 and a fifty-two week high of $23.86. The business's 50 day moving average price is $7.27 and its two-hundred day moving average price is $8.58.

Novavax (NASDAQ:NVAX - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) EPS. Sell-side analysts forecast that Novavax will post -1.46 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.